In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sinopharm nets HKD3.4bn in FOPO on HKE

Executive Summary

Two years after completing its HKD8.73bn IPO, Sinopharm Group Co. Ltd., China’s largest drug distributor, has netted HKD3.4bn ($436mm) in a secondary placement of 138mm H shares at HKD25 on the Hong Kong Stock Exchange. Proceeds will help fund the many acquisitions the company plans over the next two years to expand its distribution network.
Deal Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies